Monthly Archives: July 2014

Birx, Farmer: Global AIDS lessons can inform, equip hepatitis response

By on .

WASHINGTON, DC — Health leaders who gathered Wednesday at the White House to commemorate World Hepatitis Day agreed that recognition of the needless toll and continuing threat of that global, infectious and often deadly disease has been a long time coming. They also cited practical promise in the recent World Health Assembly Hepatitis Resolution that […]

Gilead, sofosbuvir, and hepatitis C . . . We’re reading about the high cost of living

By on .

The Treatment Action Group’s 2014 Pipeline Report released in conjunction with the 20th International AIDS Conference last week devotes three sections to the outlook for better and more accessible treatment for hepatitis C, examining the promise of new direct acting antiviral treatments, starting with sofosbuvir (marketed by Gilead pharmaceutical company as Sovaldi) being eclipsed by […]

World Hepatitis Day: Sub-Saharan Africa sees progress, but persisting risks for HBV, HBC transfusion-transmitted infections, CDC reports

By on .

More countries were screening donated blood for hepatitis B and hepatitis C across sub-Saharan Africa by 2011, than 10 years earlier but prevention of transfusion-transmitted disease remains challenged across the region, a report from the United States Center for Disease Control and Prevention released last week shows. The report, in the CDC’s Morbidity and Mortality […]

A look at AIDS 2014: Stigma and discrimination pose barriers to accessing health services

By on .

Science Speaks covered AIDS 2014 with live coverage and guest posts and is continuing this week with insights on issues raised during the week. The following post is by Laura Nyblade, of Health Policy Project, RTI International MELBOURNE, AUSTRALIA —Nearly every plenary speaker at the International AIDS Conference last week, from political leaders to scientists […]

In the wake of loss, we’re reading about six lives and legacies that moved the world closer to justice, equity and global health

By on .

Among the 298 people whose deaths in the crash MH17 last week left the world saddened and diminished, the loss of the six who were on their way to the 20th International AIDS Conference in Melbourne left a community that was founded on loss and driven by the value of all lives reflecting on what […]

AIDS 2014: Peer programs engage injection drug users in Kenya and Tanzania

By on .

Science Speaks is live-blogging from AIDS 2014 in Melbourne, Australia this week, with updates on research, policy and insights from the 20th International AIDS Conference. MELBOURNE, AUSTRALIA –  During a symposium on harm reduction and people who use drugs today, researchers from Kenya and Tanzania pointed to strategies and services to increase the participation of […]

AIDS 2014: Pediatric treatment lag demands planning, action, final plenary speaker says

By on .

Science Speaks is live-blogging from AIDS 2014 in Melbourne, Australia this week, with updates on research, policy and insights from the 20th International AIDS Conference. MELBOURNE, AUSTRALIA –   Shaffiq Essajee spoke during today’s plenary session about HIV prevention and treatment for children with a strong focus on the treatment side. “While we are seeing 60 […]

AIDS 2014: Antiretroviral treatment update kicks off final plenary session

By on .

Science Speaks is live-blogging from AIDS 2014 in Melbourne, Australia this week, with updates on research, policy and insights from the 20th International AIDS Conference. MELBOURNE, AUSTRALIA –  Professor David Cooper kicked off the final opening plenary in Melbourne today with a review on antiretroviral therapy including a look at recommended drug regimens for first- […]

AIDS 2014: Activists hold die-in to protest high price of Gilead’s hepatitis C drug

By on .

Science Speaks is live-blogging from AIDS 2014 in Melbourne, Australia through the week, with updates on research, policy and insights from the 20th International AIDS Conference. MELBOURNE, AUSTRALIA –  Activists surprised Gilead corporate executives today with a “die-in” to protest the pricing of Gilead’s hepatitis C drug, Solvaldi (sofosbuvir). As Gregg Alton, Gilead’s Executive Vice-President […]